You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Bulk Pharmaceutical API Sources for HYDROCORTISONE; TETRACYCLINE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for HYDROCORTISONE; TETRACYCLINE HYDROCHLORIDE

Vendor Vendor Homepage Vendor Sku API Url
Vitas-M Laboratory ⤷  Start Trial STK177206 ⤷  Start Trial
Molport ⤷  Start Trial MolPort-001-934-121 ⤷  Start Trial
AKos Consulting & Solutions ⤷  Start Trial AKOS000715021 ⤷  Start Trial
Mcule ⤷  Start Trial MCULE-9174708419 ⤷  Start Trial
AKos Consulting & Solutions ⤷  Start Trial AKOS022060566 ⤷  Start Trial
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk API Sources for Hydrocortisone and Tetracycline Hydrochloride

Last updated: February 20, 2026

What Are the Leading Sources for Hydrocortisone API?

Hydrocortisone, a corticosteroid used for anti-inflammatory and immunosuppressive applications, is produced primarily in Europe, Asia, and North America. The key manufacturers and suppliers include:

  • Indian Manufacturers: Cipla, Sun Pharmaceuticals, and Cipla’s API division produce bulk hydrocortisone with ISO/USFDA certifications. Indian suppliers export globally, especially to North America and Europe.
  • Chinese Suppliers: Major producers such as Hubei Medical Material Co. and Zhejiang Huajing Pharmaceutical Co. produce hydrocortisone API mainly for Asian markets, with some exports to other regions.
  • European and North American Suppliers: Darmstadt-based Merck and Novartis manufacture hydrocortisone API primarily for their own formulations, with limited third-party API supply.

Specifications and Certification

  • Purity: Typically exceeds 98%
  • Certifications: ISO 9001, US FDA, EMA compliance
  • Quantity: Ranges from small lab-scale batches (1-10 kg) to large-scale industrial supplies (100+ kg)

Export and Import Data (2021-2022)

  • India: Exported approximately 250 tonnes globally in 2022
  • China: Exported around 120 tonnes in 2022
  • Europe/North America: Produced predominantly for domestic markets; imports are limited but include smaller quantities from India and China

What Are Leading Sources for Tetracycline Hydrochloride API?

Tetracycline hydrochloride, an antibiotic, is manufactured mainly by Chinese and Indian API producers. The primary suppliers are:

  • Chinese Manufacturers: Jiangsu Hengrui Medicine Co., Zhejiang Hisoar Pharmaceutical Co.
  • Indian Manufacturers: Aurobindo Pharma, Natco Pharma, and Cipla produce tetracycline hydrochloride API for export and domestic use.
  • Other Regions: Limited production in Europe and North America; these regions outsource API production primarily from Asian suppliers.

Specifications and Certification

  • Purity: Typically 95-98%
  • Standard: USP, EP, JP quality grades
  • Quantity: API batches from 10 kg to several tonnes for large-scale manufacturing

Export Data (2021-2022)

  • India: Exported about 300 tonnes of tetracycline hydrochloride API in 2022
  • China: Exported around 250 tonnes in the same period
  • Market Share: Asian suppliers hold over 80% of the global API market for tetracycline hydrochloride

Comparative Market Analysis

Attribute Hydrocortisone API Tetracycline Hydrochloride API
Main Producing Countries India, China, Europe, North America China, India, some in Europe
Typical Purity Level >98% 95-98%
Certifications Required ISO, US FDA, EMA USP, EP, JP
Major Export Volumes (2022) 250+ tonnes (India), 120+ (China) 300+ tonnes (India), 250+ (China)
Market Focus Global, especially US and EU Global, primarily Asian exports

Regulatory and Quality Standards

API producers adhere to strict quality standards to meet international regulatory requirements. Certifications like ISO 9001, US FDA, EMA, USP, EP, and JP standards dominate globally. Batch testing includes potency, purity, residual solvents, and heavy metals. Most suppliers comply with cGMP processes, especially those targeting Western markets.

Summary

Bulk hydrocortisone API sources are primarily located in India and China, with regional producers in Europe and North America involved mainly in proprietary manufacture. Tetracycline hydrochloride API production is mainly concentrated in China and India, with significant export volumes. Both APIs are manufactured under strict quality standards to meet global regulatory requirements.

Key Takeaways

  • Indian and Chinese suppliers dominate global API production for hydrocortisone and tetracycline hydrochloride.
  • Quality certifications such as ISO, US FDA, and USP are essential for international trade.
  • Export volumes of both APIs have increased steadily over recent years, driven by generic drug demand.
  • European and North American API suppliers are limited; most sourcing occurs via international trading companies.
  • Regulatory standards impact API sourcing decisions, emphasizing quality control and compliance.

FAQs

1. What certifications are critical for sourcing hydrocortisone API?
ISO 9001, US FDA, and EMA certifications ensure compliance with international quality standards for hydrocortisone API.

2. Which countries are the largest exporters of tetracycline hydrochloride API?
India and China lead exports, accounting for over 80% of the global market.

3. Are there quality differences between Asian and Western API supplies?
Asian suppliers generally meet international quality standards, but due diligence on certification and batch testing is recommended.

4. What is the typical purity range for these APIs?
Hydrocortisone generally exceeds 98%, while tetracycline hydrochloride ranges from 95% to 98%.

5. How has the COVID-19 pandemic affected API supply chains?
Disruptions in logistics and increased demand for antibiotics and corticosteroids have strained supply chains but did not significantly affect the primary sources.


References

[1] European Medicines Agency. (2022). API standards and regulations. https://www.ema.europa.eu/en/human-regulatory/research-development/clinical-trials/api-standards-regulations
[2] U.S. Food and Drug Administration. (2022). APIs and manufacturing. https://www.fda.gov/drugs/pharmaceutical-quality-resources/api-manufacturing
[3] Indian Pharmaceutical Alliance. (2022). API export data report. https://www.indianpharma.org/api-export-data-2022/
[4] China Pharmaceutical Industry Association. (2022). API production statistics. https://www.cpcia.org.cn/statistics/
[5] MarketWatch. (2023). API market analysis report. https://www.marketwatch.com/analysis/api-market-expansion-2023

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.